- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer (clinicaltrials.gov) - Sep 19, 2012 P2, N=141, Completed, Active, not recruiting --> Terminated; low accrual N=312 --> 141
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer (clinicaltrials.gov) - Sep 19, 2012 P2, N=141, Completed, N=44 --> 132 Active, not recruiting --> Completed
- |||||||||| paclitaxel / Generic mfg.
Trial completion, Surgery, Metastases: Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva (clinicaltrials.gov) - Sep 19, 2012 P2, N=31, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Ontak (denileukin diftitox) / Eisai, TSD Japan
Enrollment change, Metastases: Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine (clinicaltrials.gov) - Sep 17, 2012 P1, N=8, Active, not recruiting, Active, not recruiting --> Completed N=10 --> 8
|